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Background: Medication adherence has an important influence on health outcomes in
patients with chronic diseases. However, few studies have been performed in Japan to
determine factors related to medication non-adherence.
Objective: The aim of this study was to identify prescription factors related to
medication non-adherence by investigating patient characteristics, all prescriptions, and
prescriptions for oral antidiabetic drugs (OADs).
Methods: A retrospective cross-sectional survey of prescription data about
implementation of dosing regimen was performed at community pharmacies engaged in
appropriate use of leftover drugs. We evaluated the amount of drugs originally prescribed
and the reduced amount after use of leftover drugs, and then calculated prescription
reduction ratio (PRR). We analyzed prescription factors contributing to non-adherence
based on the PRR.
Results: Prescription information for 1207 patients was reviewed, revealing that patients
were non-adherent to 58% of prescriptions. Lack of a drug copayment, fewer concurrent
drugs, and drugs not in single-dose packaging were associated with non-adherence.
Among the 1207 patients, 234 prescriptions for diabetes and 452 OAD formulations
were included. Forty-seven percent of prescriptions and 29% of the formulations were
non-adherent. A higher dosing frequency and preprandial administration were associated
with non-adherence. Among the OADs, adherence was lower for α-glucosidase inhibitors
and biguanides than for sulfonylureas.
Conclusions: Several factors related to patient characteristics, general drug
prescriptions, and OAD prescriptions were associated with non-adherence. Further
consideration will be needed to improve adherence to medication in Japan. Health care
providers should perform more careful monitoring of adherence in patients with the
factors identified by this study.
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INTRODUCTION
Maintaining sufficient adherence with medication is a critical
issue in determining the health outcomes of patients with chronic
diseases. In Japan, all citizens are covered by public health
insurance and have relatively low copayments (http://www.mh
lw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01_eng.pdf). Most
patients with chronic diseases consult their family doctor
regularly, and drugs are prescribed depending on the
consultation schedule. Therefore, if medication adherence
is sufficiently high, patients with chronic diseases should not
have leftover drugs. However, medication non-adherence
results in home storage of leftover drugs for various reasons
(Kardas et al., 2013), both in Japan (Kutsuma et al., 2004;
Hatanaka et al., 2009) and in other countries (Ruhoy and
Daughton, 2008; Kevin, 2010).
This situation suggests a possibility of reducing medical
expenditure. For instance, a previous study indicated that
appropriate reuse of leftover drugs could contribute to reducing
medical costs (Kutsuma et al., 2004). Furthermore, non-
adherence is linked to increased hospitalization (Juarez et al.,
2013; Shin et al., 2013), higher all-cause mortality (Chowdhury
et al., 2013; Shin et al., 2013), and higher healthcare costs
(Egede et al., 2012; Wong et al., 2014). Because of these
findings, community pharmacists have been obliged to
check and count patients’ leftover drugs from April 2012 in
Japan.
The Fukuoka City Pharmaceutical Association started the
SETSUYAKU-BAG campaign in collaboration with Kyushu
University from June 2012. This campaign has three aims:
(1) to reduce medical expenditure by promoting appropriate
reuse of leftover drugs; (2) to ascertain and improve adherence
with medication by educating patients about leftover drugs;
(3) to avoid the risk of incorrect use of accumulated leftover
drugs by patients. Our previous research (Koyanagi et al., 2013)
assessed the current situation of leftover drug retention by
adult outpatients, and proved that community pharmacists could
reduce medical costs by appropriate reuse of such drugs. Based
on our findings, we estimated the possible reduction of medical
costs for all Japan in 1 year. However, we only surveyed leftover
drugs, so we were not able to clarify the reduction rate for original
prescriptions, and the prescription factors for medication non-
adherence.
Understanding the factors contributing to non-adherence has
the potential to guide efforts and interventions for improving
the adherence of patients to their medications. In Japan, several
studies about medication adherence and non-adherence have
already been performed (Kitagawa et al., 2012; Matsumura et al.,
2012). However, these studies were relatively small in scale and
were limited to particular diseases or drugs. Many studies about
medication adherence using pharmacy claim database have been
performed in other countries (Chapman et al., 2005; Han et al.,
2012; Chowdhury et al., 2013; Sattler et al., 2013; Kirkman
et al., 2015). The medication possession ratio (MPR) or the
proportion of days covered (PDC) are common methods of
measuring medication adherence based on pharmacy refills or
claims data for chronic conditions (Andrade et al., 2006). In
Japan, we do not have a refill prescription system, and it is
difficult to utilize the pharmacy claims database. Therefore, a
different method is necessary to assess medication adherence in
Japan.
In the present study, we collected both original prescriptions
and prescription adjustment information of patients with chronic
disease who regularly consult their family doctor from 127
pharmacies for a year through the SETSUYAKU-BAG campaign.
Adherence to medications is defined as the process by which
patients take their medication as prescribed, further divided
into three quantifiable phase: initiation, implementation, and
discontinuation (Vrijens et al., 2012). We assessed prescription
factors related to non-adherence about implementation of dosing
regimen for all oral drugs and also analyzed factors related to
non-adherence for oral antidiabetic drugs (OADs). We evaluated
the extent of non-adherence by using a different method to
assess medication adherence, which was based on prescription
reduction ratio (PRR); the reduction ratio of the amount of drugs
in the original prescriptions by appropriate utilization of leftover
drugs.
MATERIALS AND METHODS
Study Design
This study was performed in Fukuoka city (1.5 million
inhabitants) in southern Japan. Between February 1, 2013 and
January 31, 2014, we implemented this study in collaboration
with Kyushu University at 645 community pharmacies that
were the Fukuoka City Pharmaceutical Association members.
Pharmacists explained the aims and procedures of this study
to eligible patients and obtained informed consent, after which
they documented the details of the explanation provided and
acquisition of consent in the medication records. Pharmacists
also gave each patient a bag (SETSUYAKU-BAG), and asked
the patient to put all leftover drugs in this bag and bring
them the next time they came to fill a prescription. An
SETSUYAKU-BAG and leftover drugs brought to pharmacies
by patients is shown in Figure 1. When a patient brought
leftover drugs to the community pharmacy, the pharmacist
inspected the medications. If they could still be used, the
pharmacist advised the patient to utilize the leftover drugs
before the expiration date. After acquiring the patient’s consent,
the pharmacist requested the patient’s doctor to adjust the
prescription(s) accordingly. The pharmacist wrote the patient’s
age, sex, and copayment for medication on a SETSUYAKU-BAG
campaign information sheet (Supplementary Figure 1) and also
wrote details of adjustments to medication amounts on a copy
of each prescription (Supplementary Figure 2). After deleting
personal information (name, birth date, insurance number, etc.),
the pharmacist sent the information sheet and prescription
copies to Kyushu University. This study was approved by the
Ethics Committees of both the Fukuoka City Pharmaceutical
Association and Kyushu University.
Data Analysis
To assess the non-adherence for oral drugs, we excluded, (1)
topical medications, (2) drugs taken as needed, (3) prescriptions
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FIGURE 1 | A SETSUYAKU-BAG and leftover drugs brought to
pharmacies by patients.
outside the national health insurance scheme. We totaled the
amount of drugs according to the original prescriptions and
the reduced amount after adjustment for leftover drugs. Among
patients with diabetes, we selected those with prescriptions for
OADs, which were defined according to standard commodity
classification of Japan (http://www.soumu.go.jp/main_content/
000294493.pdf). Drug amounts were counted by using a drug
unit (tablet, capsule, etc.). We evaluated the extent of non-
adherence by calculating the PRR after use of leftover drugs as
follows:
PRR (%) = amount of drugs reduced after adjustment for
leftover drugs/amount of drugs originally prescribed.
A MPR of 0.8 or higher is commonly used as a threshold to
define adherence (Hess et al., 2006; Karve et al., 2009). Therefore,
we considered patients to be non-adherent if the PRR was >0.2,
implying that >20% of their prescribed drugs had not been used.
A logistic regression analysis was performed to evaluate the
association of medication non-adherence, and odds ratio (OR),
95% confidence interval (CI) and C-statistic were calculated.
We separately analyzed factors for all oral drugs and for OADs.
For all oral drugs, we adjusted the total number of concurrent
drugs, patient copayment, and nonuse of single-dose packaging.
For OADs, we adjusted the total number of concurrent drugs,
number of concurrent OADs, OAD prescription days, and
nonuse of single-dose packaging. For OAD utilization, we
adjusted total number of concurrent drugs.
Data are shown as the mean± SD (range; median). Statistical
significance was assumed at p < 0.05, and precision of estimates
was assessed from the 95% confidence interval. All statistical
analyses were performed using JMP pro 11 software (SAS
Institute Inc., Cary, NC).
RESULTS
We collected data on 1376 prescriptions from 127 pharmacies.
A total of 1207 prescriptions (for 1207 patients) met the criteria
for this study. The patients included 532 males and 675 females
with a mean age of 68.3 ± 15.8 (range: 0.3–99) years. The
characteristics of the patients and their prescriptions are shown in
Table 1. The mean number of concurrent drugs and prescription
days were 5.6 ± 2.9 (range: 1–17) drugs and 27.7 ± 14.1 (range:
3–98) days, respectively. The total amount of drugs originally
prescribed was 298,020 doses and this was reduced by 80,902
doses after adjustment for utilization of leftover drugs, which was
a 27% reduction.
Factors associated with non-adherence for all oral drugs
are shown in Table 2. Among the 1207 patients, 695 (58%)
met the criteria for non-adherence. Seventy-eight percent of
patients were 60 years old or older, 56% were female, and
48% were required to make a 30% copayment for medical
costs. Seventy-five percent of prescriptions were for more
than four concurrent drugs, 82% were for <30 days, and
15% were for drugs in single-dose packaging. Multivariate
logistic regression analysis demonstrated that several factors were
associated with non-adherence. The risk of non-adherence was
higher in patients who did not have to pay drug copayment
(0%: OR= 1.67, CI= 1.12–2.50), and were prescribed fewer
concurrent drugs (<4: OR = 3.41, CI = 2.43–4.82; 4–6:
OR= 1.83, CI= 1.39–2.42). Patients with single-dose packaging
showed a lower risk of non-adherence (OR = 0.63, CI = 0.44–
0.89) than patient without single-dose packaging. The C-statistic
was 0.637–0.641.
Characteristics of the diabetic patients and their prescriptions
are also shown in Table 1. There were 234 OAD prescriptions for
234 patients, including 142 males and 92 females with a mean
age of 70.1 ± 11.3 (range: 28–89) years, and the total number of
formulations was 452. The mean number of concurrent OADs
and prescription days were 1.9 ± 0.9 (range: 1–5) drugs and
31.4 ± 12.5 (range: 7–90) days, respectively. The total amount
of OADs before adjustment was 26,357.5 doses and the reduction
was 5696 doses (23%).
Factors associated with non-adherence to treatment with
OADs are shown in Table 3. Among the 234 patients, 110 (47%)
met the criteria for non-adherence. Over 84% of patients were
60 years old or older, 39% were female, and 52% had a 30%
copayment. There were 90 prescriptions for a single OAD and
144 for multiple OADs. Seventy-four percent were prescribed
for <30 days and 18% of prescriptions were for drugs in single-
dose packaging. Based on the results of multivariate logistic
regression, no factor was associated with non-adherence. The
C-statistic was 0.664–0.680. Factors associated with OAD non-
adherence in relation to dosage and drug class are shown in
Table 4. Among 452 formulations, 132 (29%) met the criteria of
non-adherence. Fifty-eight percent were for once-daily dosing,
72% were taken postprandially, and 33% of the formulations
were for dipeptidyl peptidase-4 inhibitors (DPP4I). The risk
of non-adherence increased in drugs prescribed with a higher
dosing frequency (twice: OR= 4.82, CI= 2.81–8.36; three times:
OR= 8.64, CI= 5.10–14.92). Preprandial administration showed
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TABLE 1 | Characteristics of the patients and their prescriptions.
Patient characteristics All oral drugs OADs
Patients, n 1207 234
Age (years) 68.3 ± 15.8 (range: 0.3–99; median 70) 70.1 ± 11.3 (range: 28–89; median 70)
SEX, N (%)
Male 532 (44.1) 142 (60.7)
Female 675 (55.9) 92 (39.3)
PATIENT COPAYMENT, N (%)
0% 143 (11.8) 13 (5.6)
10% 491 (40.7) 99 (42.3)
30% 573 (47.5) 122 (52.1)
Total number of concurrent drugs 5.6 ± 2.9 (range: 1–17; median 5) 1.9 ± 0.9 (range: 1–5; median 2)
CONCURRENT OADs
Single, n (%) – 90 (38.5)
Multiple, n (%) – 144 (61.5)
Prescription days 27.7 ± 14.1 (range: 3–98; median 28) 31.4 ± 12.5 (range: 7–90; median 30)
Total number of formulations, n 6744 452
Total amount of original prescription drugs, n 298,020 26,357.5
Total amount of reduction drugs, n (%) 80,902 (27.1) 5696 (22.6)
Mean amount of original prescription drugs 246.9 ± 190.7 (range: 5–2079; median 210) 112.6 ± 95.6 (range: 7–510; median 84)
Mean amount of reduction drugs 67.0 ± 87.5 (range: 1–1744; median 42) 25.5 ± 39.5 (range: 0–231; median 7.3)
Mean PRR (%) 29.3 ± 22.1 (range: 0.2–100; median 24.8) 19.4 ± 25.4 (range: 0–100; median 9.0)
Data are represented as the mean ± SD (range; median).
OADs, oral antidiabetic drugs; PRR, prescription reduction ratio.
a higher risk of non-adherence (OR= 2.68, CI= 1.73–4.16) than
postprandial administration. Compared to sulfonylureas (SU),
α-glucosidase inhibitors (αGI), and biguanides (BG) showed a
higher risk of non-adherence (αGI: OR = 6.86, CI = 3.54–13.72;
BG: OR= 3.83, CI= 2.02–7.43). The C-statistic was 0.643–0.743.
DISCUSSION
In the present study, we investigated leftover drugs and adjusted
the prescriptions of patients by utilizing these drugs. We assessed
prescription factors related to medication non-adherence about
implementation of dosing regimen by the PRR. A high PRR
meant that the patient had a larger number of leftover drugs,
indicating non-adherence. Analysis of factors associated with
non-adherence for all oral drugs showed that 58% of patients
were non-adherent and several factors were associated with
medication non-adherence. Lack of a drug copayment and fewer
concurrent drugs were associated with non-adherence, while
single-dose packaging enhanced adherence. Among patients
using antidiabetic drugs, 47% were non-adherent, but no factors
associated with medication adherence were identified. Regarding
OAD utilization, 29% of the formulations met the criteria for
non-adherence. Patients with a lower dosing frequency for their
medications clearly showed better adherence, while preprandial
administration was associated with worse adherence. In addition,
adherence to treatment with αGI or BG was lower than for
treatment with SU.
Based on our prescription adjustment information, the
characteristics of the patients were varied and 75% of the
prescriptions for oral drugs were for four or more concurrent
drugs. Rolnick et al. examined medication adherence in patients
with multiple diseases and stated that the adherence rate varied
from 32 to 75% (Rolnick et al., 2013). Chapman et al. reported
that the long-term adherence rate was only 36% for both
antihypertensive therapy and lipid-lowering therapy (Chapman
et al., 2005). In prior studies of diabetic patients, medication
adherence rates have ranged from 45 to 78% (Curkendall et al.,
2013; Guénette et al., 2013; Kirkman et al., 2015; Simard et al.,
2015; Tunceli et al., 2015). Our findings seem to be consistent
with the results of these studies in other countries. Japan has
a different sociological and cultural background compared to
Europe and the US where most of the research on medication
adherence were performed. Although we were not able to assess
the sociological and cultural custom of the patients, it might be
suggested that non-adherence was principally dependent on the
relation of the patients’ therapeutic program and was not very
deeply influenced by the ethical norms of the society. Further
consideration will be needed to yield any findings about these
points.
We found that patients who did not have to make a drug
copayment were less likely to show adherence. Previous studies
have suggested that high drug costs (Malmenäs et al., 2013;
Kirkman et al., 2015; Simard et al., 2015; Tunceli et al., 2015)
and lower incomes (Rolnick et al., 2013; Kirkman et al., 2015)
were associated with non-adherence. In Japan, as one of the
solutions to this problems, the government has set different
patient copayment rates depending on a person’s circumstances
(ordinary citizen: 30%, elderly person: 10%, low income person:
no copayment). The lack of co-payment seems to stimulate or
oblige the patients to save up the drugs even if they do not
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TABLE 2 | Factors contributing to non-adherence for all oral drugs.
Non-adherent (PRR > 0.2) Adherent (PRR ≤ 0.2) Total Odds ratio (95% CI) P value C-statistic
n = 695 (57.6) n = 512 (42.4) n = 1207 (100)
PATIENT FACTORS
Age, n (%)
<40 48 (6.9) 29 (5.7) 77 (6.4) 1.13 (0.64–2.00) 0.682 0.637
40–59 113 (16.3) 73 (14.3) 186 (15.4) 1.02 (0.66–1.59) 0.913 –
60–74 266 (38.3) 184 (35.9) 450 (37.3) 1.02 (0.74–1.40) 0.919 –
≥75 268 (38.6) 226 (44.1) 494 (40.9) 1.00 NA –
Sex, n (%)
Male 300 (43.2) 232 (45.3) 532 (44.1) 0.90 (0.71–1.14) 0.395 0.638
Female 395 (56.8) 280 (54.7) 675 (55.9) 1.00 NA –
Patient copayment, n (%)
0% 89 (12.8) 54 (10.5) 143 (11.8) 1.67 (1.12–2.50) 0.011* 0.637
10% 270 (38.8) 221 (43.2) 491 (40.7) 1.10 (0.85–1.43) 0.452 –
30% 336 (48.3) 237 (46.3) 573 (47.5) 1.00 NA –
PRESCRIPTION FACTORS
Total number of concurrent drugs, n (%)
<4 224 (32.2) 82 (16.0) 306 (25.4) 3.41 (2.43–4.82) <0.001* 0.641
4–6 296 (42.6) 203 (39.6) 499 (41.3) 1.83 (1.39–2.42) <0.001* –
≥7 175 (25.2) 227 (44.3) 402 (33.3) 1.00 NA –
Prescription days, n (%)
≤30 565 (81.3) 426 (83.2) 991 (82.1) 1.00 NA 0.638
>30 130 (18.7) 86 (16.8) 216 (17.9) 1.12 (0.82–1.53) 0.483 –
Single-dose packaging, n (%)
Yes 75 (10.8) 106 (20.7) 181 (15.0) 0.63 (0.44–0.89) 0.008* 0.637
No 620 (89.2) 406 (79.3) 1026 (85.0) 1.00 NA –
The odds ratio (OR) and 95% confidence interval (CI) were calculated to predict the factors associated with non-adherence (PRR > 20%). Logistic regression models were adjusted for
the total number of concurrent drugs, patient copayment, and nonuse of single-dose packaging.
*Statistically significant at the 5% level. Adherence status: number (%).
PRR, prescription reduction ratio.
intend to use it, and might have led to reduced appreciation
of the importance of medication. Pharmacists should take
account of this tendency and give more careful and frequent
observation on these patients. Furthermore, it is desirable that
pharmacists confirm the necessity of their medication, evaluate
their dosing regimen and share the result with the doctors. We
think pharmacists could contribute to optimize the patients’
prescription in cooperation with doctors.
Regarding the effect of the total number of concurrent drugs
on adherence, contradictory results have been reported. In our
study, a higher total number of concurrent drugs was associated
with better adherence and this was also found by some large-
scale studies of adherence to medication (Guénette et al., 2013;
Kirkman et al., 2015; Tunceli et al., 2015). However, Chapman
et al. reported that patients were more likely to be adherent if
they took fewer medications (Chapman et al., 2005).
We also found that single-dose packaging of medication
enhanced adherence, a result that is in agreement with another
report (Hatanaka et al., 2009). There have been few studies about
the influences of single-dose packaging on medication adherence
in Japan, but it is possible that better adherence associated
with a higher total number of medications might have been
influenced by single-dose packaging. In this study, the use of
single-dose packaging increased along with the total number of
drugs prescribed (<4: 2.6%, 4–6: 10.0%,≥7: 30.6%). Thus, single-
dose packaging tended to increase along with the total number of
medications and this form of packaging for medications might
be an effective technique for enhancing adherence, especially in
polypharmacy.
A lower dosing frequency was clearly associated with better
adherence. Comparing the medication adherence of diabetic
patients between once-daily dosing and twice-daily dosing,
Tunceli et al. and Malmenäs et al. reported that twice-daily
dosing resulted in 18 and 33% lower adherence than once-
daily dosing, respectively. In these studies, once-daily dosing was
not compared with thrice-daily dosing (Malmenäs et al., 2013;
Tunceli et al., 2015). Our study revealed larger differences of
adherence in relation to dosing frequency, which were 4.8-fold
for once vs. twice and 8.6-fold for once vs. three-times.
Preprandial administration was associated with lower
medication adherence compared to postprandial administration.
Masuda et al. mentioned that one reason for non-adherence to
αGI therapy is the need to take these drugs before meals (Masuda
et al., 2011). While little has been reported about the influence of
preprandial dosing on medication adherence, αGI are frequently
prescribed in Japan and we found that αGI accounted for 14% of
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TABLE 3 | Factors contributing to non-adherence for OADs.
Non-adherent (PRR > 0.2) Adherent (PRR ≤ 0.2) Total Odds ratio (95% CI) P value C-statistic
n = 110 (47.0) n = 124 (53.0) n = 234 (100)
PATIENT FACTORS
Age, n (%)
<60 22 (20.0) 15 (12.1) 37 (15.8) 1.38 (0.58–3.34) 0.471 0.680
60–74 50 (45.5) 59 (47.6) 109 (46.6) 0.99 (0.52–1.89) 0.985 –
≥75 38 (34.5) 50 (40.3) 88 (37.6) 1.00 NA –
Sex, n (%)
Male 71 (64.5) 71 (57.3) 142 (60.7) 1.00 NA 0.680
Female 39 (35.5) 53 (42.7) 92 (39.3) 0.81 (0.46–1.41) 0.447 –
Patient copayment, n (%)
0% 7 (6.4) 6 (4.8) 13 (5.6) 1.13 (0.32–4.07) 0.849 0.675
10% 43 (39.1) 56 (45.2) 99 (42.3) 0.88 (0.49–1.61) 0.687 –
30% 60 (54.5) 62 (50.0) 122 (52.1) 1.00 NA –
PRESCRIPTION FACTORS
Number of concurrent OADs, n (%)
1 48 (43.6) 42 (33.9) 90 (38.5) 1.00 NA 0.673
2 40 (36.4) 47 (37.9) 87 (37.2) 0.69 (0.37–1.28) 0.235 –
3–5 22 (20.0) 35 (28.2) 57 (24.4) 0.57 (0.28–1.15) 0.117 –
Prescription days, n (%)
≤30 83 (75.5) 90 (72.6) 173 (73.9) 1.00 NA 0.664
>30 27 (24.5) 34 (27.4) 61 (26.1) 0.89 (0.48–1.65) 0.709 –
Single-dose packaging, n (%)
Yes 12 (10.9) 31 (25.0) 43 (18.4) 0.58 (0.25–1.31) 0.191 0.674
No 98 (89.1) 93 (75.0) 191 (81.6) 1.00 NA –
The odds ratio (OR) and 95% confidence interval (CI) were calculated to predict the factors associated with non-adherence (PRR > 20%). Logistic regression models were adjusted for
the total number of concurrent drugs, number of concurrent OADs, OAD prescription days, and nonuse of single-dose packaging.
Adherence status: number (%).
OADs, oral antidiabetic drugs; PRR, prescription reduction ratio.
TABLE 4 | Factors contributing to OAD non-adherence associated with dosage and drug class.
Non-adherent (PRR > 0.2) Adherent(PRR ≤ 0.2) Total Odds ratio (95% CI) P value C-statistic
n = 132 (29.2) n = 320 (70.8) n = 452 (100)
DOSING FREQUENCY, N (%)
Once 35 (26.5) 225 (70.3) 260 (57.5) 1.00 NA 0.743
Twice 40 (30.3) 53 (16.6) 93 (20.6) 4.82 (2.81–8.36) <0.001* –
Three times 57 (43.2) 42 (13.1) 99 (21.9) 8.64 (5.10–14.92) <0.001* –
ADMINISTRATION TIME, N (%)
Preprandial 56 (42.4) 70 (21.9) 126 (27.9) 2.68 (1.73–4.16) <0.001* 0.643
Postprandial 76 (57.6) 250 (78.1) 326 (72.1) 1.00 NA –
TYPE OF OAD, N (%)
SU 23 (17.4) 100 (31.3) 123 (27.2) 1.00 NA 0.714
BG 35 (26.5) 38 (11.9) 73 (16.2) 3.83 (2.02–7.43) <0.001* –
DPP4I 29 (22.0) 119 (37.2) 148 (32.7) 1.04 (0.57–1.93) 0.889 –
αGI 40 (30.3) 25 (7.8) 65 (14.4) 6.86 (3.54–13.72) <0.001* –
Others 5 (3.8) 38 (11.9) 43 (9.5) 0.57 (0.18–1.50) 0.264 –
The odds ratio (OR) and 95% confidence interval (CI) were calculated to predict the factors associated with non-adherence (PRR > 20%). Logistic regression models were adjusted for
the total number of concurrent drugs.
*Statistically significant at the 5% level.
Adherence status: number (%).
OADs, oral antidiabetic drugs; PRR, prescription reduction ratio; SU, sulfonylureas; BG, biguanides; DPP4I, dipeptidyl peptidase-4 inhibitors; αGI, α-glucosidase inhibitors.
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all the OAD formulations. As long as this situation continues in
Japan, it seems reasonable for pharmacists to apply more careful
adherence monitoring to these drugs.
Among the OADs, adherence was less likely with αGI and
BG than with SU. An effect of OAD class on adherence has
been found in several previous studies. Simard et al. stated that
adherence was lower with αGI than other OADs, while adherence
was higher with BG than SU, αGI, or meglitinides (Simard et al.,
2015). A prospective study performed in the United Kingdom
assessed 60 patients for 2 months and showed that adherence
was lower with BG than SU (White et al., 2012). Curkendall
et al. stated that patients taking SU or thiazolidinediones (TZD)
were less likely to be adherent than those taking saxagliptin (a
DPP4I) (Curkendall et al., 2013). A high dosing frequency and/or
preprandial administration is required with αGI and BG. In
Japan, the standard regimen for αGI is administration three times
daily just before each meal, while BG are taken twice or three
times daily before or after meals. Based on these regimens, our
results seem understandable. We think there are three reasons
for poor adherence to αGI therapy: (1) administration just before
each meal; (2) dosing three times a day; and (3) gastrointestinal
adverse effects. In Japan, metformin might be less commonly
used than in Europe and the USA, since we found it was
prescribed in 16% of all the OAD formulations. Along with the
high dosing frequency of BG, we think this might be one of
the reasons for non-adherence to BG therapy. According to our
findings, DPP4I and other drugs (including TZD) showed no
significant differences to SU with respect to non-adherence.
The present study differed from previous studies in the
following points. We attempted to use the PRR which was
different from standard method to assess medication non-
adherence. To determine drug utilization, we inspected the actual
leftover drugs rather than performing a database survey, and
calculated PRR. TheMPR is the ratio of the number of prescribed
days to the number of days for which the drug should have
been prescribed during the equivalent period. On the other
hand, the PRR is the reduction ratio of the amount of drugs in
the original prescriptions by appropriate utilization of leftover
drugs. Thus, the PRR expresses the reverse concept to the MPR.
In Japan where a refill prescription system is not adopted,
fewer medication adherence studies have been performed by
using the pharmacy claims database than in other countries
because of the difficulty in mining this database. In fact, Andrade
et al. mentioned that medication adherence study using such a
database had not been performed in Japan (Andrade et al., 2006).
In Japan, all community pharmacists check and count patients’
leftover drugs as part of their regular duties. This means that
assessment of medication adherence by calculating PRRmight be
useful in Japan. Furthermore, our findings seem to be consistent
with the results of medication adherence which were evaluated
based on standard index (Chapman et al., 2005; Curkendall et al.,
2013; Guénette et al., 2013; Malmenäs et al., 2013; Rolnick et al.,
2013; Kirkman et al., 2015; Simard et al., 2015; Tunceli et al.,
2015). Although both actual drug consumption and the quantity
prescribed during the investigation period should be surveyed as
the optimum method of assessing medication adherence, until
access, and utilization of the pharmacy claims database become
easier, we think it seems reasonable to use PRR as a simple index
for evaluating non-adherence in Japan.
Our study had several limitations. First, our sample size was
smaller than in other studies (Chapman et al., 2005; Curkendall
et al., 2013; Guénette et al., 2013; Malmenäs et al., 2013; Rolnick
et al., 2013; Kirkman et al., 2015; Simard et al., 2015; Tunceli et al.,
2015). Regarding the effects of age and sex on adherence, previous
studies have provided contradictory results. Several studies have
shown that older patients (Curkendall et al., 2013; Guénette et al.,
2013; Malmenäs et al., 2013; Rolnick et al., 2013; Kirkman et al.,
2015; Simard et al., 2015; Tunceli et al., 2015) and male patients
(Chapman et al., 2005; Curkendall et al., 2013; Malmenäs et al.,
2013; Rolnick et al., 2013; Kirkman et al., 2015; Tunceli et al.,
2015) had higher adherence. In our study, there was no effect
of these factors, but it might be possible that the sample size
influenced these results. Second, we used a cross-sectional design
to investigate leftover drugs and the study was also limited to one
city in Japan, so we cannot exclude the possibility that different
results might be obtained if the same survey was performed at
another time or place with different patients. The evaluation
period of non-adherence depends on the prescription interval
when the PRR is used, and it was shorter than in previous studies
(Chapman et al., 2005; Curkendall et al., 2013; Guénette et al.,
2013; Malmenäs et al., 2013; Rolnick et al., 2013; Kirkman et al.,
2015; Simard et al., 2015; Tunceli et al., 2015), which set an
evaluation period of 1 year or more. Thus, it seems possible
that our findings are less precise than those of the other studies.
Third, the PRR may overestimate medication non-adherence.
This study investigated patients who brought prescriptions and
leftover drugs to pharmacies. We only collected the prescriptions
of patients with leftover drugs and we did not include patients
who were adherent without leftover drugs. It might be a possible
biases because of only counting patients who returned leftover
drug. In Japan, the ratio of patients not retaining leftover drugs
was reported to be ∼44% in 2013 by Ministry of Health, Labour
and Welfare, Japan (http://www.mhlw.go.jp/file/05-Shingikai-
12404000-Hokenkyoku-Iryouka/0000092092.pdf). On the other
hand, we cannot exclude the possibility that there were more
patients who did not bring their leftover drugs. Finally, although
medication adherence should be evaluated about patient factors
(including patients’ beliefs and mood), clinician factors, and
treatment factors (Stack et al., 2008, 2011; Gadkari and
McHorney, 2012), we were not able to assess these factors. In
this study, we were only able to collect prescription data, and we
could not obtain the information about clinicians and patients’
treatment because of Japanese prescription form. In addition,
we did not perform questionnaire survey for patients, so it was
difficult to assess the elements about patients’ beliefs and mood.
In this study, we assessed prescription factors associated
with medication non-adherence about implementation of dosing
regimen by the PRR. Our findings fit reasonably with the
results of previous studies. The PRR is not a standard index of
medication adherence, but it might be able to measure actual
medication taking more accurately. Further consideration of
adherence to medication will be needed in Japan, but it seems
reasonable for health care providers (such as pharmacists) to
perform more careful adherence monitoring in the following
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situations: (1) no drug copayment and (2) drugs taken frequently
and/or before meals. In addition, they should not assume
that patients who use fewer medications are more likely to
be adherent. Furthermore, when patients have a complicated
regimen with multiple drugs, single-dose packagingmight be one
effective method of enhancing adherence.
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